Do Different Populations of Rectal Cancer Exist?

  • Vincenzo Valentini
  • Francesco Cellini
  • Maria Cristina Barba
  • Ruud van Stiphout
Chapter

Abstract

The impact of new treatments for rectal cancer has substantially improved patients’ clinical outcomes in the last few years, but still worldwide colorectal cancer remains the third most common. In 2000, colorectal cancer was responsible for 7.9% of the world’s cancer deaths, with 492,000 deaths; it accounted for 9.4% of the world’s new cancers registered, with 945,000 cases diagnosed (Parkin Lancet Oncol 2(9):533–543, 2001; National Cancer Institute: PDQ® Rectal Cancer Treatment. National Cancer Institute, Bethesda (2011) http://cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional).

References

  1. 1.
    Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533–543CrossRefPubMedGoogle Scholar
  2. 2.
    National Cancer Institute: PDQ® Rectal Cancer Treatment. National Cancer Institute, Bethesda (2011) http://cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional
  3. 3.
    Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC et al (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29:3163–3172CrossRefPubMedGoogle Scholar
  4. 4.
    Wang Y, Cummings B, Catton P et al (2005) Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol 77:126–132CrossRefPubMedGoogle Scholar
  5. 5.
    Mohiuddin M, Ahmad N, Marks G (1993) A selective approach to adjunctive therapy for cancer of the rectum. Int J Radiat Oncol Biol Phys 27(4):765–772CrossRefPubMedGoogle Scholar
  6. 6.
    Schwaab J, Horisberger K, Ströbel P (2011) Expression of transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 11:363CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lammering G, Buijsen J (2012) What biochemical and molecular biological factors have greater relevance to treatment decisions? In: Valentini V, Schmoll H-J, van de Velde CJH (eds) Multidisciplinary management of rectal cancer – questions and answers. Springer, Berlin/New YorkGoogle Scholar
  8. 8.
    Valentini V, van Stiphout R, Lammering G et al (2015) Two-year disease free vs pathological complete response as a surrogate endpoint by using pooled data of randomized trials for locally advanced rectal cancer. Radiother Oncol 114(3):302–9. doi:  10.1016/j.radonc.2015.02.001. Epub 2015 Feb 21
  9. 9.
    Sargent D, Shi Q, Yothers G (2011) Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47(7):990–996. Epub 2011 Jan 21CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Valentini V, Coco C, Picciocchi A (2002) Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53(3):664–674CrossRefPubMedGoogle Scholar
  11. 11.
    Capirci C, Valentini V, Cionini L (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72(1):99–107. Epub 11 Apr 2008CrossRefPubMedGoogle Scholar
  12. 12.
    Sebag-Montefiore D, Bujko K, Valentini V (2009) Rectal cancer multidisciplinary management: evidences and future landscape. Radiother Oncol 92(2):145–147. Epub 2009 Jul 10CrossRefPubMedGoogle Scholar
  13. 13.
    van Stiphout R, Roelofs E, Dekker A (2012) How to share data and promote a rapid learning health medicine? In: Multidisciplinary management of rectal cancer – questions and answers. Springer 2011Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Vincenzo Valentini
    • 1
    • 2
  • Francesco Cellini
    • 3
  • Maria Cristina Barba
    • 1
    • 2
  • Ruud van Stiphout
    • 4
  1. 1.Department of RadiotherapyUniversità Cattolica Sacro CuoreRomeItaly
  2. 2.Policlinico Universitario ‘A. Gemelli’RomeItaly
  3. 3.Radioterapia OncologicaUniversità Campus BiomedicoRomeItaly
  4. 4.Department of Radiation Oncology (MAASTRO)GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre+MaastrichtThe Netherlands

Personalised recommendations